Amyloid β and APP as biomarkers for Alzheimer's disease

Experimental Gerontology

Volumn 45, Issue 1, 2010, Pages 23-29

  Zetterberg, Henrik ^a   Blennow, Kaj ^a   Hanse, Eric ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Alzheimer's disease; Amyloid; Biomarkers; Cerebrospinal fluid; Long term potentiation

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; GAMMA SECRETASE; ISOPROTEIN; OLIGOMER; PRESENILIN; TAU PROTEIN;

ALZHEIMER DISEASE; CARBOXY TERMINAL SEQUENCE; CELL LOSS; CLINICAL FEATURE; COGNITIVE DEFECT; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; DISEASE PREDISPOSITION; DISEASE SEVERITY; FAMILIAL DISEASE; GENE MUTATION; HUMAN; NERVE CELL; NERVE CELL DEGENERATION; NERVE CELL NETWORK; NEUROFIBRILLARY TANGLE; PATHOPHYSIOLOGY; POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DETERMINATION; REVIEW; SENILE PLAQUE; SENSITIVITY AND SPECIFICITY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; HUMANS; LONG-TERM POTENTIATION;

EID: 71849099881     PISSN: 05315565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exger.2009.08.002     Document Type: Review

References (109)

1. Abrahamsson T., Gustafsson B., and Hanse E. Reversible synaptic depression in developing rat CA3 CA1 synapses explained by a novel cycle of AMPA silencing-unsilencing. J. Neurophysiol. 98 (2007) 2604-2611
2. Almeida C.G., Tampellini D., Takahashi R.H., Greengard P., Lin M.T., Snyder E.M., and Gouras G.K. Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol. Dis. 20 (2005) 187-198
3. Andreasen N., Minthon L., Davidsson P., Vanmechelen E., Vanderstichele H., Winblad B., and Blennow K. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch. Neurol. 58 (2001) 373-379
4. Andreasen N., and Zetterberg H. Amyloid-related biomarkers for Alzheimer's disease. Curr. Med. Chem. 15 (2008) 766-771
5. Andreasson U., Portelius E., Andersson M.E., Blennow K., and Zetterberg H. Aspects of beta-amyloid as a biomarker for Alzheimer's disease. Biomarkers Med. 1 (2007) 59-78
6. Ballatore C., Lee V.M., and Trojanowski J.Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 8 (2007) 663-672
7. Bateman R.J., Munsell L.Y., Morris J.C., Swarm R., Yarasheski K.E., and Holtzman D.M. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat. Med. 12 (2006) 856-861
8. Bateman, R.J., Siemers, E.R., Mawuenyega, K.G., Wen, G., Browning, K.R., Sigurdson, W.C., Yarasheski, K.E., Friedrich, S.W., Demattos, R.B., May, P.C., Paul, S.M., Holtzman, D.M., 2009. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann. Neurol. doi:10.1002/ana.21623.
9. Blennow K., de Leon M.J., and Zetterberg H. Alzheimer's disease. Lancet 368 (2006) 387-403
10. Buerger, K., Frisoni, G., Uspenskaya, O., Ewers, M., Zetterberg, H., Geroldi, C., Binetti, G., Johannsen, P., Rossini, P.M., Wahlund, L.O., Vellas, B., Blennow, K., Hampel, H., 2009. Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's disease neuroimaging initiative (E-ADNI). Exp. Gerontol. doi:10.1016/j.exger.2009.06.003.
11. Campbell W.A., Yang H., Zetterberg H., Baulac S., Sears J.A., Liu T., Wong S.T., Zhong T.P., and Xia W. Zebrafish lacking Alzheimer presenilin enhancer 2 (Pen-2) demonstrate excessive p53-dependent apoptosis and neuronal loss. J. Neurochem. 96 (2006) 1423-1440
12. Chang E.H., Savage M.J., Flood D.G., Thomas J.M., Levy R.B., Mahadomrongkul V., Shirao T., Aoki C., and Huerta P.T. AMPA receptor downscaling at the onset of Alzheimer's disease pathology in double knockin mice. Proc. Natl. Acad. Sci. USA 103 (2006) 3410-3415
13. Chapman P.F., White G.L., Jones M.W., Cooper-Blacketer D., Marshall V.J., Irizarry M., Younkin L., Good M.A., Bliss T.V., Hyman B.T., Younkin S.G., and Hsiao K.K. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci. 2 (1999) 271-276
14. Cheng L., Yin W.J., Zhang J.F., and Qi J.S. Amyloid beta-protein fragments 25-35 and 31-35 potentiate long-term depression in hippocampal CA1 region of rats in vivo. Synapse 63 (2009) 206-214
15. Chiocco M.J., and Lamb B.T. Spatial and temporal control of age-related APP processing in genomic-based beta-secretase transgenic mice. Neurobiol. Aging 28 (2007) 75-84
16. Cullen W.K., Suh Y.H., Anwyl R., and Rowan M.J. Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments. Neuroreport 8 (1997) 3213-3217
17. Davidsson P., and Blennow K. Neurochemical dissection of synaptic pathology in Alzheimer's disease. Int. Psychogeriatr. 10 (1998) 11-23
18. De Felice F.G., Vieira M.N., Bomfim T.R., Decker H., Velasco P.T., Lambert M.P., Viola K.L., Zhao W.Q., Ferreira S.T., and Klein W.L. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc. Natl. Acad. Sci. USA 106 (2009) 1971-1976
19. De Felipe J., Marco P., Fairen A., and Jones E.G. Inhibitory synaptogenesis in mouse somatosensory cortex. Cereb. Cortex 7 (1997) 619-634
20. De Strooper B. Aph-1, Pen-2, and nicastrin with presenilin generate an active gamma-secretase complex. Neuron 38 (2003) 9-12
21. Fagan A.M., Mintun M.A., Mach R.H., Lee S.Y., Dence C.S., Shah A.R., LaRossa G.N., Spinner M.L., Klunk W.E., Mathis C.A., DeKosky S.T., Morris J.C., and Holtzman D.M. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 59 (2006) 512-519
22. Fluhrer R., Multhaup G., Schlicksupp A., Okochi M., Takeda M., Lammich S., Willem M., Westmeyer G., Bode W., Walter J., and Haass C. Identification of a beta-secretase activity, which truncates amyloid beta-peptide after its presenilin-dependent generation. J. Biol. Chem. 278 (2003) 5531-5538
23. Fonseca M.I., Zhou J., Botto M., and Tenner A.J. Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J. Neurosci. 24 (2004) 6457-6465
24. Forsberg A., Engler H., Almkvist O., Blomquist G., Hagman G., Wall A., Ringheim A., Langstrom B., and Nordberg A. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol. Aging 29 (2008) 1456-1465
25. Francis R., McGrath G., Zhang J., Ruddy D.A., Sym M., Apfeld J., Nicoll M., Maxwell M., Hai B., Ellis M.C., Parks A.L., Xu W., Li J., Gurney M., Myers R.L., Himes C.S., Hiebsch R., Ruble C., Nye J.S., and Curtis D. Aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev. Cell 3 (2002) 85-97
26. Freeman S.H., Raju S., Hyman B.T., Frosch M.P., and Irizarry M.C. Plasma Abeta levels do not reflect brain Abeta levels. J. Neuropathol. Exp. Neurol. 66 (2007) 264-271
27. Frisoni G.B., Prestia A., Zanetti O., Galluzzi S., Romano M., Cotelli M., Gennarelli M., Binetti G., Bocchio L., Paghera B., Amicucci G., Bonetti M., Benussi L., Ghidoni R., and Geroldi C. Markers of Alzheimer's disease in a population attending a memory clinic. Alzheimer Dement. 5 (2009) 307-317
28. Fukuyama R., Mizuno T., Mori S., Nakajima K., Fushiki S., and Yanagisawa K. Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer's disease patients. Eur. Neurol. 43 (2000) 155-160
29. Georganopoulou D.G., Chang L., Nam J.M., Thaxton C.S., Mufson E.J., Klein W.L., and Mirkin C.A. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc. Natl. Acad. Sci. USA 102 (2005) 2273-2276
30. Groc L., and Choquet D. AMPA and NMDA glutamate receptor trafficking: multiple roads for reaching and leaving the synapse. Cell Tissue Res. 326 (2006) 423-438
31. Gustafson D.R., Skoog I., Rosengren L., Zetterberg H., and Blennow K. Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J. Neurol. Neurosurg. Psychiatry 78 (2007) 461-464
32. Hampel H., Teipel S.J., Fuchsberger T., Andreasen N., Wiltfang J., Otto M., Shen Y., Dodel R., Du Y., Farlow M., Moller H.J., Blennow K., and Buerger K. Value of CSF beta-amyloid 1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol. Psychiatry 9 (2004) 705-710
33. Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., and Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5 (2006) 228-234
34. Hansson O., Zetterberg H., Buchhave P., Andreasson U., Londos E., Minthon L., and Blennow K. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 23 (2007) 316-320
35. Herukka S.K., Hallikainen M., Soininen H., and Pirttila T. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 64 (2005) 1294-1297
36. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., Jones R.W., Bullock R., Love S., Neal J.W., Zotova E., and Nicoll J.A. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372 (2008) 216-223
37. Holsinger R.M., McLean C.A., Collins S.J., Masters C.L., and Evin G. Increased beta-Secretase activity in cerebrospinal fluid of Alzheimer's disease subjects. Ann. Neurol. 55 (2004) 898-899
38. Holsinger R.M., Lee J.S., Boyd A., Masters C.L., and Collins S.J. CSF BACE1 activity is increased in CJD and Alzheimer disease versus [corrected] other dementias. Neurology 67 (2006) 710-712
39. Hsia A.Y., Masliah E., McConlogue L., Yu G.Q., Tatsuno G., Hu K., Kholodenko D., Malenka R.C., Nicoll R.A., and Mucke L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. USA 96 (1999) 3228-3233
40. Hu X., Hicks C.W., He W., Wong P., Macklin W.B., Trapp B.D., and Yan R. Bace1 modulates myelination in the central and peripheral nervous system. Nat. Neurosci. 9 (2006) 1520-1525
41. Hussain I., Powell D., Howlett D.R., Tew D.G., Meek T.D., Chapman C., Gloger I.S., Murphy K.E., Southan C.D., Ryan D.M., Smith T.S., Simmons D.L., Walsh F.S., Dingwall C., and Christie G. Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol. Cell. Neurosci. 14 (1999) 419-427
42. Irizarry M.C. Biomarkers of Alzheimer disease in plasma. NeuroRx 1 (2004) 226-234
43. Kadir A., Andreasen N., Almkvist O., Wall A., Forsberg A., Engler H., Hagman G., Larksater M., Winblad B., Zetterberg H., Blennow K., Langstrom B., and Nordberg A. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann. Neurol. 63 (2008) 621-631
44. Kamenetz F., Tomita T., Hsieh H., Seabrook G., Borchelt D., Iwatsubo T., Sisodia S., and Malinow R. APP processing and synaptic function. Neuron 37 (2003) 925-937
45. Kanai M., Matsubara E., Isoe K., Urakami K., Nakashima K., Arai H., Sasaki H., Abe K., Iwatsubo T., Kosaka T., Watanabe M., Tomidokoro Y., Shizuka M., Mizushima K., Nakamura T., Igeta Y., Ikeda Y., Amari M., Kawarabayashi T., Ishiguro K., Harigaya Y., Wakabayashi K., Okamoto K., Hirai S., and Shoji M. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. Ann. Neurol. 44 (1998) 17-26
46. Kessels H.W., and Malinow R. Synaptic AMPA receptor plasticity and behavior. Neuron 61 (2009) 340-350
47. Kirazov E., Kirazov L., Bigl V., and Schliebs R. Ontogenetic changes in protein level of amyloid precursor protein (APP) in growth cones and synaptosomes from rat brain and prenatal expression pattern of APP mRNA isoforms in developing rat embryo. Int. J. Dev. Neurosci. 19 (2001) 287-296
48. Kitazume S., Tachida Y., Oka R., Shirotani K., Saido T.C., and Hashimoto Y. Alzheimer's beta-secretase, beta-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase. Proc. Natl. Acad. Sci. USA 98 (2001) 13554-13559
49. Kitazume S., Tachida Y., Oka R., Kotani N., Ogawa K., Suzuki M., Dohmae N., Takio K., Saido T.C., and Hashimoto Y. Characterization of alpha 2,6-sialyltransferase cleavage by Alzheimer's beta-secretase (BACE1). J. Biol. Chem. 278 (2003) 14865-14871
50. Klyubin I., Betts V., Welzel A.T., Blennow K., Zetterberg H., Wallin A., Lemere C.A., Cullen W.K., Peng Y., Wisniewski T., Selkoe D.J., Anwyl R., Walsh D.M., and Rowan M.J. Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J. Neurosci. 28 (2008) 4231-4237
51. Koffie R.M., Meyer-Luehmann M., Hashimoto T., Adams K.W., Mielke M.L., Garcia-Alloza M., Micheva K.D., Smith S.J., Kim M.L., Lee V.M., Hyman B.T., and Spires-Jones T.L. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl. Acad. Sci. USA 106 (2009) 4012-4017
52. Lacor P.N., Buniel M.C., Furlow P.W., Clemente A.S., Velasco P.T., Wood M., Viola K.L., and Klein W.L. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J. Neurosci. 27 (2007) 796-807
53. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., and Klein W.L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 95 (1998) 6448-6453
54. Lannfelt L., Blennow K., Zetterberg H., Batsman S., Ames D., Harrison J., Masters C.L., Targum S., Bush A.I., Murdoch R., Wilson J., and Ritchie C.W. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 7 (2008) 779-786
55. Lauren J., Gimbel D.A., Nygaard H.B., Gilbert J.W., and Strittmatter S.M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457 (2009) 1128-1132
56. Lee C.C., Kuo Y.M., Huang C.C., and Hsu K.S. Insulin rescues amyloid beta-induced impairment of hippocampal long-term potentiation. Neurobiol. Aging 30 (2009) 377-387
57. Lewczuk, P., Kamrowski-Kruck, H., Peters, O., Heuser, I., Jessen, F., Popp, J., Burger, K., Hampel, H., Frolich, L., Wolf, S., Prinz, B., Jahn, H., Luckhaus, C., Perneczky, R., Hull, M., Schroder, J., Kessler, H., Pantel, J., Gertz, H.J., Klafki, H.W., Kolsch, H., Reulbach, U., Esselmann, H., Maler, J.M., Bibl, M., Kornhuber, J., Wiltfang, J., 2008. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol. Psychiatry doi:10.1038/mp.2008.84.
58. Li Q., and Sudhof T.C. Cleavage of amyloid-beta precursor protein and amyloid-beta precursor-like protein by BACE 1. J. Biol. Chem. 279 (2004) 10542-10550
59. Lichtenthaler S.F., Dominguez D.I., Westmeyer G.G., Reiss K., Haass C., Saftig P., De Strooper B., and Seed B. The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. J. Biol. Chem. 278 (2003) 48713-48719
60. Mattsson, N., Axelsson, M., Haghighi, S., Malmestrom, C., Wu, G., Anckarsater, R., Sankaranarayanan, S., Andreasson, U., Fredrikson, S., Gundersen, A., Johnsen, L., Flaby, T., Tarkowski, A., Trysberg, E., Wallin, A., Anckarsater, H., Lycke, J., Andersen, O., Simon, A., Blennow, K., Zetterberg, H., 2009a. Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis. Mult. Scler. doi:10.1177/1352458508100031.
61. Mattsson N., and Zetterberg H. Future screening for incipient Alzheimer's disease - the influence of prevalence on test performance. Eur. Neurol. 62 (2009) 200-203
62. Mattsson N., Zetterberg H., Hansson O., Andreasen N., Parnetti L., Jonsson M., Herukka S.K., van der Flier W.M., Blankenstein M.A., Ewers M., Rich K., Kaiser E., Verbeek M., Tsolaki M., Mulugeta E., Rosen E., Aarsland D., Visser P.J., Schroder J., Marcusson J., de Leon M., Hampel H., Scheltens P., Pirttila T., Wallin A., Jonhagen M.E., Minthon L., Winblad B., and Blennow K. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302 (2009) 385-393
63. Mayeux R., Honig L.S., Tang M.X., Manly J., Stern Y., Schupf N., and Mehta P.D. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 61 (2003) 1185-1190
64. Megias M., Emri Z., Freund T.F., and Gulyas A.I. Total number and distribution of inhibitory and excitatory synapses on hippocampal CA1 pyramidal cells. Neuroscience 102 (2001) 527-540
65. Mehta P.D., Pirttila T., Mehta S.P., Sersen E.A., Aisen P.S., and Wisniewski H.M. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch. Neurol. 57 (2000) 100-105
66. Mehta P.D., Pirttila T., Patrick B.A., Barshatzky M., and Mehta S.P. Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci. Lett. 304 (2001) 102-106
67. Moreno-Flores M.T., Medina M., and Wandosell F. Expression of presenilin 1 in nervous system during rat development. J. Comp. Neurol. 410 (1999) 556-570
68. Neves G., Cooke S.F., and Bliss T.V. Synaptic plasticity, memory and the hippocampus: a neural network approach to causality. Nat. Rev. Neurosci. 9 (2008) 65-75
69. Nikolaev A., McLaughlin T., O'Leary D.D., and Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 457 (2009) 981-989
70. Olsson A., Hoglund K., Sjogren M., Andreasen N., Minthon L., Lannfelt L., Buerger K., Moller H.J., Hampel H., Davidsson P., and Blennow K. Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp. Neurol. 183 (2003) 74-80
71. Perry V.H., and O'Connor V. C1q: the perfect complement for a synaptic feast?. Nat. Rev. Neurosci. 9 (2008) 807-811
72. Pitschke M., Prior R., Haupt M., and Riesner D. Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy. Nat. Med. 4 (1998) 832-834
73. Portelius E., Zetterberg H., Gobom J., Andreasson U., and Blennow K. Targeted proteomics in Alzheimer's disease: focus on amyloid-beta. Expert Rev. Proteomics 5 (2008) 225-237
74. Portelius E., Brinkmalm G., Tran A.J., Zetterberg H., Westman-Brinkmalm A., and Blennow K. Identification of novel APP/Abeta isoforms in human cerebrospinal fluid. Neurodegener. Dis. 6 (2009) 87-94
75. Priller C., Bauer T., Mitteregger G., Krebs B., Kretzschmar H.A., and Herms J. Synapse formation and function is modulated by the amyloid precursor protein. J. Neurosci. 26 (2006) 7212-7221
76. Prince J.A., Zetterberg H., Andreasen N., Marcusson J., and Blennow K. APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. Neurology 62 (2004) 2116-2118
77. Raymond C.R., Ireland D.R., and Abraham W.C. NMDA receptor regulation by amyloid-beta does not account for its inhibition of LTP in rat hippocampus. Brain Res. 968 (2003) 263-272
78. Reiman E.M., Chen K., Liu X., Bandy D., Yu M., Lee W., Ayutyanont N., Keppler J., Reeder S.A., Langbaum J.B., Alexander G.E., Klunk W.E., Mathis C.A., Price J.C., Aizenstein H.J., DeKosky S.T., and Caselli R.J. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. USA 106 (2009) 6820-6825
79. Ringman J.M., Younkin S.G., Pratico D., Seltzer W., Cole G.M., Geschwind D.H., Rodriguez-Agudelo Y., Schaffer B., Fein J., Sokolow S., Rosario E.R., Gylys K.H., Varpetian A., Medina L.D., and Cummings J.L. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 71 (2008) 85-92
80. Rolstad S., Nordlund A., Eckerstrom C., Gustavsson M.H., Zetterberg H., and Wallin A. Biomarkers in relation to cognitive reserve in patients with mild cognitive impairment-proof of concept. Dement. Geriatr. Cogn. Disord. 27 (2009) 194-200
81. Schoonenboom N.S., Mulder C., Van Kamp G.J., Mehta S.P., Scheltens P., Blankenstein M.A., and Mehta P.D. Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same?. Ann. Neurol. 58 (2005) 139-142
82. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81 (2001) 741-766
83. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., and Selkoe D.J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14 (2008) 837-842
84. Shoji M., Matsubara E., Kanai M., Watanabe M., Nakamura T., Tomidokoro Y., Shizuka M., Wakabayashi K., Igeta Y., Ikeda Y., Mizushima K., Amari M., Ishiguro K., Kawarabayashi T., Harigaya Y., Okamoto K., and Hirai S. Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease. J. Neurol. Sci. 158 (1998) 134-140
85. Sinha S., Anderson J.P., Barbour R., Basi G.S., Caccavello R., Davis D., Doan M., Dovey H.F., Frigon N., Hong J., Jacobson-Croak K., Jewett N., Keim P., Knops J., Lieberburg I., Power M., Tan H., Tatsuno G., Tung J., Schenk D., Seubert P., Suomensaari S.M., Wang S., Walker D., John V., et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402 (1999) 537-540
86. Snyder E.M., Nong Y., Almeida C.G., Paul S., Moran T., Choi E.Y., Nairn A.C., Salter M.W., Lombroso P.J., Gouras G.K., and Greengard P. Regulation of NMDA receptor trafficking by amyloid-beta. Nat. Neurosci. 8 (2005) 1051-1058
87. Stevens B., Allen N.J., Vazquez L.E., Howell G.R., Christopherson K.S., Nouri N., Micheva K.D., Mehalow A.K., Huberman A.D., Stafford B., Sher A., Litke A.M., Lambris J.D., Smith S.J., John S.W., and Barres B.A. The classical complement cascade mediates CNS synapse elimination. Cell 131 (2007) 1164-1178
88. Strozyk D., Blennow K., White L.R., and Launer L.J. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60 (2003) 652-656
89. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., and Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30 (1991) 572-580
90. Ting J.T., Kelley B.G., Lambert T.J., Cook D.G., and Sullivan J.M. Amyloid precursor protein overexpression depresses excitatory transmission through both presynaptic and postsynaptic mechanisms. Proc. Natl. Acad. Sci. USA 104 (2007) 353-358
91. Townsend M., Shankar G.M., Mehta T., Walsh D.M., and Selkoe D.J. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J. Physiol. 572 (2006) 477-492
92. Townsend M., Mehta T., and Selkoe D.J. Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J. Biol. Chem. 282 (2007) 33305-33312
93. Waites C.L., Craig A.M., and Garner C.C. Mechanisms of vertebrate synaptogenesis. Annu. Rev. Neurosci. 28 (2005) 251-274
94. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., and Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539
95. Walsh D.M., Townsend M., Podlisny M.B., Shankar G.M., Fadeeva J.V., El Agnaf O., Hartley D.M., and Selkoe D.J. Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J. Neurosci. 25 (2005) 2455-2462
96. Vanderstichele H., Van Kerschaver E., Hesse C., Davidsson P., Buyse M.A., Andreasen N., Minthon L., Wallin A., Blennow K., and Vanmechelen E. Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 7 (2000) 245-258
97. Wasling P., Daborg J., Riebe I., Andersson M., Portelius E., Blennow K., Hanse E., and Zetterberg H. Synaptic retrogenesis and amyloid-beta in Alzheimer's disease. J. Alzheimers Dis. 16 (2009) 1-14
98. Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., Teplow D.B., Ross S., Amarante P., Loeloff R., Luo Y., Fisher S., Fuller J., Edenson S., Lile J., Jarosinski M.A., Biere A.L., Curran E., Burgess T., Louis J.C., Collins F., Treanor J., Rogers G., and Citron M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286 (1999) 735-741
99. Verheijen J.H., Huisman L.G., van Lent N., Neumann U., Paganetti P., Hack C.E., Bouwman F., Lindeman J., Bollen E.L., and Hanemaaijer R. Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay. Clin. Chem. 52 (2006) 1168-1174
100. Verwey N.A., van der Flier W.M., Blennow K., Clark C., Sokolow S., De Deyn P.P., Galasko D., Hampel H., Hartmann T., Kapaki E., Lannfelt L., Mehta P.D., Parnetti L., Petzold A., Pirttila T., Saleh L., Skinningsrud A., Swieten J.C., Verbeek M.M., Wiltfang J., Younkin S., Scheltens P., and Blankenstein M.A. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann. Clin. Biochem. 46 (2009) 235-240
101. Willem M., Garratt A.N., Novak B., Citron M., Kaufmann S., Rittger A., DeStrooper B., Saftig P., Birchmeier C., and Haass C. Control of peripheral nerve myelination by the beta-secretase BACE1. Science 314 (2006) 664-666
102. Wong H.K., Sakurai T., Oyama F., Kaneko K., Wada K., Miyazaki H., Kurosawa M., De Strooper B., Saftig P., and Nukina N. Beta Subunits of voltage-gated sodium channels are novel substrates of beta-site amyloid precursor protein-cleaving enzyme (BACE1) and gamma-secretase. J. Biol. Chem. 280 (2005) 23009-23017
103. Xiao M.Y., Wasling P., Hanse E., and Gustafsson B. Creation of AMPA-silent synapses in the neonatal hippocampus. Nat. Neurosci. 7 (2004) 236-243
104. Yan R., Bienkowski M.J., Shuck M.E., Miao H., Tory M.C., Pauley A.M., Brashier J.R., Stratman N.C., Mathews W.R., Buhl A.E., Carter D.B., Tomasselli A.G., Parodi L.A., Heinrikson R.L., and Gurney M.E. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 402 (1999) 533-537
105. Zetterberg H., Wahlund L.O., and Blennow K. Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci. Lett. 352 (2003) 67-69
106. Zetterberg H., Campbell W.A., Yang H.W., and Xia W. The cytosolic loop of the {gamma}-secretase component presenilin enhancer 2 protects zebrafish embryos from apoptosis. J. Biol. Chem. 281 (2006) 11933-11939
107. Zetterberg H. Is plasma amyloid-beta a reliable biomarker for Alzheimer's disease?. Recent Pat. CNS Drug Discov. 3 (2008) 109-111
108. Zetterberg H., Andreasson U., Hansson O., Wu G., Sankaranarayanan S., Andersson M.E., Buchhave P., Londos E., Umek R.M., Minthon L., Simon A.J., and Blennow K. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch. Neurol. 65 (2008) 1102-1107
109. Zhong Z., Ewers M., Teipel S., Burger K., Wallin A., Blennow K., He P., McAllister C., Hampel H., and Shen Y. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch. Gen. Psychiatry 64 (2007) 718-726